Have you noticed, CG has quietly delivered us a Chrissy present. The SP was about 25 cents when she took over as chair 07/21 and although the SP has tanked about 76%, according to the ASX announcement last week, this wiped out 43 million 8 and 14 cent options held by the previous management and chair, so we have a nice dilution reversal that also partly offsets the dilution from the 30% discount at the last cap raise and the 3 million 6 cent options CG got at the AGM. CG also gave herself a $100k salary increase so she already has her reward. Now all we need is for DMD recruiting to be completed on time so the P2b trial results will be available by next Christmas. Then we will all be rewarded. JG must give us a clear update on enrolment by March. If enrolment is going to plan, trading volume will surely be back up to the millions per day and that should produce a significant uplift in the SP, maybe back to 25 cents where it was in ’21.
We should not expect the SP to move significantly until trading volume is back up to the millions daily and that will not happen until the HNWs (high net worths) return, and that will not happen until their advisors tell them ANP is within 3-6 months of announcing P2b trial results. HNWs are sophisticated investors who already have ANP on their radar because they understand and believe in the antisense technology. Their advisors will not be wasting their client’s time talking about a mouse study, a patent filing or the change in the company’s name to a horse.
The DMD trial momentum undoubtedly suffered a significant loss of momentum last year when the two people directly responsible for it both apparently rather abruptly left the company, however they were eventually replaced by Dr Andrew McKenzie. Was he at the AGM? McKensie must be flat out driving the CRO and keeping the Principal Investigators focussed and motivated, but I haven’t found anything about his activities or intentions. It would be good to hear a report from him as well as from JG.
